Piper Sandler analyst Edward Tenthoff says his top pick Crispr Therapeutics ended 2019 with cash of $943M. Enrollment continues for the company's wholly-owned CD19 CAR-T CTX110 in B-cell malignancies with data this summer, Tenthoff tells investors in a research note. Further, Crispr's second off-the-shelf, gene edited CAR-T CTX120 has entered the clinic and an investigational new drug filing is expected for third CAR-T, CTX130 (CD70) for solid tumors in mid 2020, adds the analyst. He reiterates an Overweight rating on shares of Crispr Therapeutics with a $104 price target.